Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
نویسندگان
چکیده
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months vs.8.45months, P = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results.
منابع مشابه
Autoimmune Hemolytic Anemia preceding the Diagnosis of Primary Central Nervous System Lymphoma
In this study, a 2.5-year-old boy suffering from a febrile seizure with normal laboratory tests and a history of immune hemolytic anemia was examined. Brain MRI demonstrated some tumors in the frontal, parietal, and occipital lobe that corroborated the pathology results of primary central nervous system lymphoma for the patient. The patient was treated with high- dose of Methotrexate. Our re...
متن کاملManagement of refractory or relapsed primary central nervous system lymphoma (Review).
Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin's lymphoma arising in the central nervous system. Combined methotrexate-based chemoradiotherapy is the standard treatment for PCNSL, resulting in a median overall survival of 25-51 months. Failure of first-line treatment has been reported in most patients with PCNSL. Salvage therapy improves outcome; however, since many different ...
متن کاملCombined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
The overall response rates and long-term survival of primary central nervous system lymphoma (PCNSL) are still significantly inferior to the results achieved in similar subtypes of extranodal non-Hodgkin's lymphoma. It is clearly necessary to investigate new therapeutic methods on PCNSL. We encountered three patients histologically documented PCNSL as diffuse large B-cell lymphoma (DLBCL). They...
متن کاملTreatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy
BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin's lymphoma (NHL). The aim was to evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in PCNSL after systemic R-IDARAM and intrathecal immunochemotherapy with deferred radiotherapy. RESULTS The response rate was 94% with 17 (89%) complete responses and 1 (5%) par...
متن کاملPoint/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma?
Primary central nervous system lymphoma (PCNSL) is a relatively rare form of extra-nodal non-Hodgkin’s lymphoma that accounts for approximately 4% of primary central nervous system tumors. Treatment with high-dose methotrexate-based chemotherapeutic regimens have resulted in response rates of 60-70% or higher and long-term survival in 15-30% of patients. – 4 While PCNSL is sensitive to radiatio...
متن کامل